Viewing Study NCT04184050


Ignite Creation Date: 2025-12-24 @ 5:24 PM
Ignite Modification Date: 2026-05-27 @ 12:36 PM
Study NCT ID: NCT04184050
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-05
First Post: 2019-11-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma in Relapse View
None Multiple Myeloma View
None Multiple Myeloma of Bone View
None Multiple Myeloma With Failed Remission View
Keywords: